Related Experiment Video

Updated: Sep 5, 2025

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

17.8K

Therapy with mesenchymal stem cell transplantation in multiple sclerosis is ready for prime time: No

Antonio Uccelli1, Mark S Freedman2

  • 1Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy/Ospedale Policlinico San Martino IRCCS, Genoa, Italy.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|July 5, 2022
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

20.7K
Hypoxic Preconditioning of Marrow-derived Progenitor Cells As a Source for the Generation of Mature Schwann Cells
10:16

Hypoxic Preconditioning of Marrow-derived Progenitor Cells As a Source for the Generation of Mature Schwann Cells

Published on: June 14, 2017

7.4K

Related Experiment Videos

Last Updated: Sep 5, 2025

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

17.8K
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
10:49

Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury

Published on: September 18, 2011

20.7K
Hypoxic Preconditioning of Marrow-derived Progenitor Cells As a Source for the Generation of Mature Schwann Cells
10:16

Hypoxic Preconditioning of Marrow-derived Progenitor Cells As a Source for the Generation of Mature Schwann Cells

Published on: June 14, 2017

7.4K

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.0K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K

Articles linked to this work by shared authors, journal, and citation graph.

Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years.

Multiple sclerosis and related disorders·2026

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Persistent differences in initial diagnostic trajectory for Black and Hispanic individuals presenting with multiple sclerosis between 2020 and 2023.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Taking another look: LBSL diagnosed in adulthood masquerading as multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

A community-validated tool for clinical outcome calculation in multiple sclerosis: Consensus development and scenario-specific recommendations.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Implementation of a pilot online educational program to identify paramagnetic rim lesions.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Time-dependent divergence in infection risks among patients with multiple sclerosis treated with fumarates versus anti-CD20 monoclonal antibodies.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Automated speech analysis reveals progressive linguistic changes associated with subsequent gray matter loss in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

A Clinic-Level Intervention May Promote Methadone Patients' Consistent Daily Adherence to Their Dosing Schedules.

Substance use & addiction journal·2026

Combined umbilical cord-derived mesenchymal stem cell exosome and cell therapy in heart failure with reduced ejection fraction.

Regenerative medicine·2026

Magnetic drug targeting in post-operative human paranasal sinuses: a CFD-DPM study.

Expert opinion on drug delivery·2026

How mobile units are shaping opioid treatment experiences: Insights from patients of mobile and traditional opioid treatment programs.

Journal of substance use and addiction treatment·2026

The promise and perils of a single IRB in multi-center clinical trials: The PEPPER trial experience.

Contemporary clinical trials·2026

Once-weekly oral islatravir plus lenacapavir: clinical considerations for individualized use.

Journal of acquired immune deficiency syndromes (1999)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us